Table 1

Multivariate analysis of variables associated with neutropaenia

VariablesNeutropaenia
(n=208)
No neutropaenia
(n=779)
UnivariateMultivariate
OR (95% CI)P value*OR (95% CI)Adjusted p value†
Significant variables in univariate analysis
 Lymphopaenia, n (%)157 (75.5)373 (47.9)3.34 (2.37 to 4.72)<0.00014.41 (2.51 to 11.5)0.001
 Thrombocytopaenia, n (%)73 (35.8)102 (13.1)3.68 (2.58 to 5.25)<0.00014.11 (2.57 to 10.3)0.0006
 Low C3, n (%)101 (59.1)250 (44.1)1.83 (1.29 to 2.59)0.00061.91 (1.03 to 4.37)0.26
 Coombs test +, n (%)67 (48.6)116 (24.5)2.91 (1.96 to 4.32)<0.00011.29 (0.69 to 2.60)0.9
 Low C4, n (%)96 (56.5)249 (44.5)1.62 (1.15 to 2.29)0.0061.09 (0.54 to 2.22)0.99
Variables suggested to be associated with neutropaenia in SLE
 Oral ulcers, n (%)51 (24.6)207 (26.8)0.89 (0.63 to 1.27)0.531.28 (0.65 to 2.70)0.84
 Susceptibility to infections, n (%)13 (7.6)49 (8.5)0.89 (0.47 to 1.68)0.720.86 (0.24 to 2.65)0.95
 Anti-Ro/SSA antibodies, n (%)75 (45.2)209 (40.5)1.21 (0.85 to 1.72)0.291.28 (0.70 to 2.53)0.80
 Azathioprine, n (%)76 (40)280 (42.0)0.92 (0.66 to 1.28)0.630.90 (0.43 to 1.78)0.92
 Cyclophosphamide, n (%)43 (24.2)168 (27.2)0.85 (0.58 to 1.26)0.420.57 (0.23 to 1.16)0.98
 Methotrexate, n (%)43 (24.6)155 (26.2)0.92 (0.62 to 1.35)0.661.45 (0.66 to 3.50)0.67
 Mycophenolate mofetil, n (%)67 (36.8)237 (35.8)1.05 (0.74 to 1.47)0.790.85 (0.39 to 1.74)0.96
 Rituximab, n (%)16 (9.2)53 (9.2)1.00 (0.56 to 1.80)1.000.94 (0.27 to 2.95)0.55
  • Comparison between patients with neutropaenia (n=208) and without neutropaenia (n=779) in multivariate analysis. Significant variables in univariate analysis and variables suggested to be associated with neutropaenia in SLE according to literature were included in multivariate analysis.

  • Values with p< 0.05 are indicated in bold.

  • *Difference between patients with and without neutropaenia using χ2 test for qualitative variables and Mann-Whitney test for quantitative variables.

  • †Adjustment for multiple testing was performed with the Benjamini and Hochberg method.